These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8891152)

  • 1. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay.
    Boucher CA; Keulen W; van Bommel T; Nijhuis M; de Jong D; de Jong MD; Schipper P; Back NK
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2404-9. PubMed ID: 8891152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inclusion of full length human immunodeficiency virus type 1 (HIV-1) gag sequences in viral recombinants applied to drug susceptibility phenotyping.
    Robinson LH; Gale CV; Kleim JP
    J Virol Methods; 2002 Jul; 104(2):147-60. PubMed ID: 12088824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates.
    Kellam P; Larder BA
    Antimicrob Agents Chemother; 1994 Jan; 38(1):23-30. PubMed ID: 8141575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recombinant virus assay: a rapid assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates].
    Qin SL; Arendt V; Hemmer R; Schneider F; Wang AX; Sheng RY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Oct; 24(5):523-6. PubMed ID: 12905778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors.
    Shi C; Mellors JW
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2781-5. PubMed ID: 9420060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single-loop recombinant pseudotyped-virus-based assay to detect HIV-1 phenotypic resistance.
    Wu S; Yan P; Yan Y; Qiu L; Xie M
    Arch Virol; 2015 Jun; 160(6):1385-95. PubMed ID: 25795166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.
    Garcia-Perez J; Sanchez-Palomino S; Perez-Olmeda M; Fernandez B; Alcami J
    J Med Virol; 2007 Feb; 79(2):127-37. PubMed ID: 17177310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors.
    Walter H; Schmidt B; Korn K; Vandamme AM; Harrer T; Uberla K
    J Clin Virol; 1999 Jun; 13(1-2):71-80. PubMed ID: 10405894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma.
    Vázquez-Rosales G; García Lerma JG; Yamamoto S; Switzer WM; Havlir D; Folks TM; Richman DD; Heneine W
    AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1191-200. PubMed ID: 10480632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.
    Winters MA; Shafer RW; Jellinger RA; Mamtora G; Gingeras T; Merigan TC
    Antimicrob Agents Chemother; 1997 Apr; 41(4):757-62. PubMed ID: 9087484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates.
    Jellinger RM; Shafer RW; Merigan TC
    J Infect Dis; 1997 Mar; 175(3):561-6. PubMed ID: 9041326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs.
    de Jong JJ; Goudsmit J; Lukashov VV; Hillebrand ME; Baan E; Huismans R; Danner SA; ten Veen JH; de Wolf F; Jurriaans S
    AIDS; 1999 Jan; 13(1):75-80. PubMed ID: 10207547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5).
    Hachiya A; Aizawa-Matsuoka S; Tanaka M; Takahashi Y; Ida S; Gatanaga H; Hirabayashi Y; Kojima A; Tatsumi M; Oka S
    Antimicrob Agents Chemother; 2001 Feb; 45(2):495-501. PubMed ID: 11158746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
    Harrigan PR; Kinghorn I; Bloor S; Kemp SD; Nájera I; Kohli A; Larder BA
    J Virol; 1996 Sep; 70(9):5930-4. PubMed ID: 8709214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.
    Hertogs K; de Béthune MP; Miller V; Ivens T; Schel P; Van Cauwenberge A; Van Den Eynde C; Van Gerwen V; Azijn H; Van Houtte M; Peeters F; Staszewski S; Conant M; Bloor S; Kemp S; Larder B; Pauwels R
    Antimicrob Agents Chemother; 1998 Feb; 42(2):269-76. PubMed ID: 9527771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.
    Trivedi V; Von Lindern J; Montes-Walters M; Rojo DR; Shell EJ; Parkin N; O'Brien WA; Ferguson MR
    AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1291-300. PubMed ID: 18844463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy.
    Parkin NT; Lie YS; Hellmann N; Markowitz M; Bonhoeffer S; Ho DD; Petropoulos CJ
    J Infect Dis; 1999 Sep; 180(3):865-70. PubMed ID: 10438382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.